文献速递肾移植肾小球疾病

CFHR5肾病所致C3肾小球肾炎患者肾移植后的临床病程与结局

Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

本研究回顾性分析17例携带CFHR5肾病奠基突变的肾移植患者,随访30年。结果显示10年和15年患者生存率分别为100%和77.8%,尽管复发率较高,但76.5%的患者在中位120个月后移植肾仍有功能,且复发与移植肾丢失无显著关联。

要点

  • CFHR5肾病肾移植后复发常见,但长期移植肾存活率良好。
  • 蛋白尿与移植肾丢失显著相关(P=0.025)。
  • 复发与镜下血尿(P=0.001)和蛋白尿(P=0.018)相关。

核心结论

  • CFHR5肾病患者肾移植后虽常见复发,但长期结局良好,支持继续将肾移植作为肾脏替代治疗选择。

研究设计与样本

  • 回顾性病例系列研究,纳入17例携带CFHR5肾病奠基突变的肾移植患者,随访30年。

主要发现

  • 研究时和移植时平均年龄分别为58.6±9.9岁和46.7±8.8岁。
  • 10年和15年患者生存率分别为100%和77.8%。
  • 功能移植肾患者中蛋白尿占33.3%,镜下血尿占58.3%,血清补体水平均正常。
  • 确诊复发和可能复发分别为16.6%和52.9%,但76.5%的患者在中位120个月后移植肾仍有功能。
  • 总复发与移植肾丢失无关(P=0.171),但与镜下血尿(P=0.001)和蛋白尿(P=0.018)相关;移植肾丢失与蛋白尿相关(P=0.025)。

临床怎么用

  • CFHR5肾病患者可考虑肾移植,但需监测复发及蛋白尿。

局限性

  • 回顾性设计,样本量小(17例),随访中心单一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complement factor H-related protein 5 (CFHR5) nephropathy is an inherited renal disease characterized by microscopic and synpharyngitic macroscopic haematuria, C3 glomerulonephritis and renal failure. It is caused by an internal duplication of exons 2-3 within the CFHR5 gene resulting in dysregulation of the alternative complement pathway. The clinical characteristics and outcomes of transplanted patients with this rare familial nephropathy remain unknown. METHODS: This is a retrospective case series study of 17 kidney transplant patients with the established founder mutation, followed-up over a span of 30 years. RESULTS: The mean (±SD) age of patients at the time of the study and at transplantation was 58.6 ± 9.9 and 46.7 ± 8.8 years, respectively. The 10- and 15-year patient survival rates were 100 and 77.8%, respectively. Proteinuria was present in 33.3% and microscopic haematuria in 58.3% of patients with a functional graft. Serum complement levels were normal in all. 'Confirmed' and 'likely' recurrence of CFHR5 nephropathy were 16.6 and 52.9%, respectively; however, 76.5% of patients had a functional graft after a median of 120 months post-transplantation. Total recurrence was not associated with graft loss (P = 0.171), but was associated with the presence of microscopic haematuria (P = 0.001) and proteinuria (P = 0.018). Graft loss was associated with the presence of proteinuria (P = 0.025). CONCLUSIONS: We describe for the first time the clinical characteristics and outcome of patients with CFHR5 nephropathy post-transplantation. Despite the recurrence of CFHR5 nephropathy, we provide evidence for a long-term favourable outcome and support the continued provision of kidney transplantation as a renal replacement option in patients with CFHR5 nephropathy.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Frangou E, Varnavidou-Nicolaidou A, Petousis P, et al. Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy. Nephrol Dial Transplant. 2019. PMID: 30844074. doi:10.1093/ndt/gfz021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。